Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 280-472-4 | CAS number: 83524-75-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Reproductive/developmental toxicity screening study: NOAEL (systemic toxicity and reproductve toxicity) >= 1000 mg/kg bw/d, according OECD 422, GLP compliance, 2022, K1
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08 Sep 2021 - 27 Dec 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted July 2016
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- (CD:SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories (Raleigh, NC)
- Females nulliparous and non-pregnant: yes
- Age at study initiation: (P) approx. 12 wks
- Weight at study initiation: (P) Males: 334.9 - 452.1 g; Females: 241.9 - 273.8 g
- Housing: group housed, males were individually housed three days prior to cohabitation
- Diet: Purina Certified Rodent Diet, LabDiet 5002, ad libitum
- Water: tap water, ad libitum
- Acclimation period: 25 d
ENVIRONMENTAL CONDITIONS
- Temperature: 70 to 74 °F (ca. 21.1 - 23.3 °C)
- Humidity: 43 to 66 %
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: September 28, 2021 To: December 27, 2021 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test article was prepared at concentrations of 20, 60, and 200 mg/mL. The prepared test article was stored refrigerated (2-8 °C) in accordance with the results of the pre-study stability assessment and residual formulations were disposed of after the expiration date.
VEHICLE
- Concentration in vehicle: 20, 60, and 200 mg/mL
- Amount of vehicle (if gavage): 5.0 mL/kg (group 1, 2, 3); 5.7 mL/kg (group 4)
- Purity: Deionized water - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: max. 14 d
- Proof of pregnancy: vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged: individually
- Start of mating: Study day 15 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples for analysis of stability were collected from formulations prepared on September 20, 2021, stored at room temperature and refrigerated, transferred to the designated test site (at room temperature) and analyzed after 7 and 28 days. Aliquots from each storage sample were analyzed for concentration and the results compared to the concentration determined initially.
- Duration of treatment / exposure:
- - Males: Beginning from day 1 until the day prior to termination (30 d)
- undelivered females: until GD 23
- delivered females: until PND 13
- Pups: not directly dosed - Frequency of treatment:
- daily, 7 days a week
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Control (Group 1)
- Dose / conc.:
- 100 mg/kg bw/day
- Remarks:
- Low (Group 2)
- Dose / conc.:
- 300 mg/kg bw/day
- Remarks:
- Mid (Group 3)
- Dose / conc.:
- 1 000 mg/kg bw/day
- Remarks:
- High (Group 4)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Prior to blood collection for clinical pathology evaluation, F0 animals were fasted overnight (approximately 12 to 22 hours).
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once weekly and for dams on GD 0, 7, 14, 21 and PND 7 and 14
- Dams were evaluated for reduced maternal care or abnormal maternal behavior beginning on PND 0.
BODY WEIGHT: Yes
- Time schedule for examinations: once weekly, beginning on day 1, and on the day of termination (fasted body weight)
- Dams were weighed on GD 0, 7, 14 and 21, and on PND 1, 4, 7, and 13
FOOD CONSUMPTION:
- Quantitative food consumption parameters were recorded for F0 animals during the premating and post-mating periods (including gestation and lactation periods) to coincide with body weight collection intervals. (given in g/Day)
NEUROBEHAVIORAL ASSESSMENTS:
- No. of animals: 5 animals per sex per dose
- Animal selection: The first 5 males per group were utilized, and 5 females per group were selected based on their parturition date.
- Time schedule: Day 29 (males) and PND 11 +/- 1 (females)
- Parameters tested:
> Spontaneous Locomotor Activity
> Functional Observational Battery
> Grip Strength
CLINICAL PATHOLOGY:
- No. of animals: 5 animals per sex per dose
- Time schedule: Males: on Day of termination (Day 31); Females: PND 14
- Anesthetized with carbon dioxide/oxygen (CO2/O2, 70/30%)
- Parameters examined:
> Haematology (Erythrocyte count, Hemoglobin, Hematocrit, Leukocyte count (total), Leukocyte differential (absolute), Platelet count, Reticulocyte count (absolute), Mean corpuscular volume, Mean corpuscular hemoglobin, Mean corpuscular hemoglobin concentration)
> Coagulation (Activated partial thromboplastin time, Fibrinogen, Prothrombin time)
> Serum chemistry (Alanine aminotransferase, Albumin, Aspartate aminotransferase, Bile acids, Bilirubin, Blood urea nitrogen, Calcium, Chloride, Cholesterol, Creatinine, Glucose, Inorganic phosphate, Potassium, Sodium, Total protein)
THYROID HORMONE EVALUATION:
- On the day of scheduled termination, each F0 animal was anesthetized with CO2/O2 and blood was collected from the vena cava or aorta
- On PND 4, trunk blood was collected from two culled pups per litter. For dams with more than two pups to be culled, blood was collected from up to two additional pups and pooled.
- On PND 13, blood was collected via intracardiac puncture from two pups per litter (one male and one female whenever possible), except for one Dam who only had one pup available at PND 13 for collection. - Oestrous cyclicity (parental animals):
- Vaginal lavage samples were collected daily from F0 females for 2 weeks (Day 1 through Day 15) prior to cohabitation. The examinations continued until evidence of mating was observed, or until the 14-day cohabitation period was completed. A vaginal lavage sample was collected on the day of necropsy for all F0 females, except one female (control group) who did not have a sample collected. Samples were stained and examined microscopically for determination of the stage of the estrous cycle.
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 8 pups/litter (4/sex/litter as nearly as possible), culled pups were terminated and discarded
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
- external abnormalities
- number of live and dead pups of each sex
- clinical observations
- body weight was recorded on PND 0, 1, 4, 7, and 13
- Anogenital distance was measured on PND 1
- nipple/areola retention was measured for male pups on PND 13
- Collection of blood from two culled pups per litter, where possible for for possible future evaluation of thyroid hormones
GROSS EXAMINATION OF DEAD PUPS:
- yes, for external abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals on Day 31
- Maternal animals: All surviving animals on PND 14
- Animals were weighed prior to necropsy, sedated with CO2/O2, and exsanguinated.
GROSS NECROPSY
- not specified
- Tissues collected: see Table 1
- Tissue Processing: All gross lesions from all groups , all reproductive tissues from the control and high dose groups, and all preserved tissues designated for histopathologic evaluation in Table 1 from 5 animals/sex/group in the control and high dose groups
HISTOPATHOLOGY / ORGAN WEIGHTS
- 5 animals/sex/dose
- see Table 1 - Postmortem examinations (offspring):
- SACRIFICE/NECROPSY/HISTOPATHOLOGY:
- F1 offspring culled on PND 4 were terminated via decapitation and discarded without further examination.
- Following blood collection on PND 13, one pup/sex/litter, when available, was terminated via CO2 inhalation and the thyroid gland (with parathyroid embedded and attached to the trachea) was collected. The tissue was fixed in 10% neutral buffered formalin (NBF) for one day before the trachea was removed; the thyroid gland (with parathyroids) was weighed post-fixation and then stored in 10% NBF for possible histopathological examination.
- All remaining pups were terminated via CO2 inhalation and discarded without further examination. - Statistics:
- PROVANTIS-COLLECTED DATA:
- normality was determined by the Shapiro-Wilks test
- homogeneity of variances was determined by Levene's test
- normally distributed parametric data: ANOVA F-test followed by a Dunnett's test
- not normally-distributed nonparametric data: Kruskal-Wallis test followed by a Wilcoxon tests
and the Bonferroni-Holm method
- All statistical tests were performed at the 0.05 level of significance (p < 0.05), after accounting for multiple comparisons where indicated.
FOB:
- for scoring variables and yes/no variables: chi-square test
- for variables classified as having continuous responses: one-way fixed effects analysis of variance (ANOVA), with dose group as the fixed effect
- for variables recorded as count data: square root transformation (√(value+0.5)) was applied to the data prior to fitting the one-way ANOVA model.
MOTOR ACTIVITY DATA:
- one-way parametric analysis of variance (ANOVA) with a fixed dose group effect was fitted to the measurements
- Shapiro-Wilk test for normality
- Levene’s test for constant variance
- Under the parametric one-way ANOVA approach, Dunnett’s test was performed
- Under the nonparametric approach, a Kruskal-Wallis test was applied - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Test article-related clinical observations were limited to black feces observed in all animals receiving ≥ 100 mg/kg beginning as early as Day 2 and continuing through termination. One female in the 0, 300, and 1000 mg/kg groups and two females in the 100 mg/kg group had a ventral mass develop during gestation. With the exception of the 300 mg/kg female, the mass was no longer present at the time of scheduled termination; this was not considered to be test article-related as the incidence rate was similar across all groups including controls. Occurrences of rales, eye discharge, mouth discharge, and scabbing were deemed incidental as they were limited to a single animal and did not persist. Alopecia is a common clinical observation for this strain of rat and was noted in all groups. One female in the 100 mg/kg group displayed reduced maternal care which resulted in the loss of the entire litter by PND 1.
- Mortality:
- no mortality observed
- Description (incidence):
- All animals survived until scheduled removal from study at Day 31 (males), removal for failure to deliver (GD 24), or PND 14 (delivered females).
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no test article-related effects on body weights and body weight changes for males.
There were no test article-related effects on female body weight or body weight gains during the pre-mating period and gestation; body weights and body weight changes during the lactation period from PND 0 through 14 were comparable across groups, including control. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Test article administration did not affect male food consumption. A statistically significantly higher food consumption was noted for females receiving ≥100 mg/kg group during the first week of study (Days 1-8) and for females in the 100 mg/kg group from GD 7-14. Increases in food consumption were not considered to be related to test article administration as they were not dose-dependent, and consumption was comparable with controls for the remainder of the study periods, including lactation.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test article-related findings noted in the hematology, coagulation, or serum chemistry parameters. Any statistically significant or apparent differences between test article groups and control group were not considered test article related due to small magnitude of difference, absence of a dose response, and/or general overlap in magnitude of individual values with controls.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test article-related findings noted in the hematology, coagulation, or serum chemistry parameters. Any statistically significant or apparent differences between test article groups and control group were not considered test article related due to small magnitude of difference, absence of a dose response, and/or general overlap in magnitude of individual values with controls.
- Endocrine findings:
- no effects observed
- Description (incidence and severity):
- TSH and T4 concentrations were generally within one standard deviation or just outside of the zero-dose average levels indicating that the test material does not significantly affect the levels of TSH or T4 for adults (males at Day 31) or pups (PND 13).
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- A statistically significant difference in home cage posture for males receiving ≥ 100 mg/kg was attributed to test article administration because the difference was due to one 0 mg/kg animal with a score of 0 (awake, alert, without rearing) while all other animals had a score of -1 (sleeping, resting, recumbent). Awake or alert and sleeping or resting are normal rodent home cage behaviors.
A statistically significantly higher number of lines crossed when assessed in the open field was noted for the 1000 mg/kg females. The difference from controls was slight, and there were no corroborating effects on locomotor activity observed; therefore, the difference was not considered to be test article-related.
There were no treatment-related differences in grip strength between all groups when compared to controls.
There were no toxicologically relevant effects on locomotor activity.
Some statistically significant differences for females when analyzed per 5-minute interval. As there were no corresponding differences in total session counts, and/or some differences were attributed to high individual variability, the differences in interval counts from controls were not considered to be test article-related or toxicologically relevant.
One male (300 mg/kg) had an unusually high number of rearing counts in the 55-60 minute interval, which contributed to a very high standard error for this group within the interval and for habituation. One female (300 mg/kg) had much lower locomotor activity counts for all endpoints than all other animals in the group, which contributed to overall lower mean scores. The observed individual variability was considered to be incidental in nature. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One male (1000 mg/kg) was observed with bilateral small (0.5×) epididymides and testes. Small epididymides correlated with bilateral marked ductal atrophy microscopically whereas small testes correlated with bilateral marked atrophy of the germinal epithelium. As this was noted in only one male and are known to be a spontaneous lesion in Sprague Dawley rats, this was considered an incidental finding. However, atrophy of the epididymal ducts was associated with a lack of sperm; as a result, the male was unable to sire a litter.
All F0 female uterine tissue sections from the 0 mg/kg and 1000 mg/kg dose groups had microscopic findings compatible with placental implantations; the uterus of one female (0 mg/kg) was not examined. These microscopic findings were multifocal areas of large vacuolated and pigmented macrophages in the deep myometrium. These microscopic changes are normal findings in multiparous females after parturition, and therefore, unrelated to test article exposure. - Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A mammary mass was observed for one female (300 mg/kg) corresponding to a fibroadenoma microscopically. Fibroadenomas are common spontaneous mammary tumor commonly seen in Sprague Dawley rats and, therefore, not considered to be related to test material exposure.
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- There were no test article-related effects on the mean cycle length, number of cycles, or length of estrus. All females were cycling normally including the females that failed to produce a litter.
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Reproductive parameters were not influenced by test article administration. There was no test article-related difference in the precoital interval or gestation length.
The female mating index was 100% for the 0, 100, and 300 mg/kg groups and 80% for the 1000 mg/kg group. However, one female successfully delivered a litter although evidence of mating was not observed. When adjusted, the female mating index was 90% for the 1000 mg/kg group. The failure of a second female to produce a litter was related to infertility of the male. As such, the female mating index was comparable between all groups.
Test article administration had no effect on the female fertility index. The female fertility index was 80%, 100%, 90%, and 100% for the 0, 100, 300, and 1000 mg/kg groups, respectively. At termination, no signs of implantation were observed for the two females in the 0 mg/kg group and one female from the 300 mg/kg group. - Dose descriptor:
- NOAEL
- Remarks:
- systemic toxicity
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive toxicity
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test article-related clinical observations. Bruising and discolored skin, which is commonly associated with normal maternal care, was observed for a few pups in the 0, 300, and 1000 mg/kg groups. Other findings, such as damaged toes, thin, and scabbing, were not considered to be treatment-related as they were limited to a single pup within a litter and/or a single group (including controls).
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- There were no decreases in viability or survival between PND 0-4 as indicated by a ≥ 95% survival index across all groups; six pups in the 100 mg/kg group and four pups in the 300 mg/kg group died during this period. Within the 100 mg/kg group, six pups were dead on PND 0 and five pups were dead on PND 1 for one female (100 mg/kg), resulting in a whole litter loss.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Overall pup body weights, by litter, were consistent between groups. There were no test article-related differences in male or female pup body weights. Similarly, body weight changes for all pups, and when evaluated by sex, were comparable to controls.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- no effects observed
- Description (incidence and severity):
- There was no treatment-related effect on the anogenital distance for male or female pups. The mean distance was within 0.1 mm for males and females for all treated groups in comparison to the control pups.
- Nipple retention in male pups:
- no effects observed
- Description (incidence and severity):
- The mean number of retained nipples/areolae for male pups was similar across all groups. There was no discernable difference in the total number of pups or litters containing at least one pup with retained nipples/areolae.
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- The total number of pups born (live and dead on PND 0) was comparable at all dosages. The litter sex ratio was comparable across all groups, including controls.
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Reproductive effects observed:
- no
- Conclusions:
- The no observable adverse effect level (NOAEL) for systemic and reproductive toxicity in F0 males and females was above 1000 mg/kg bw/day in this study. Due to the absence of toxic effects at the highed tested dose, an exact NOAEL was not determinable.
- Executive summary:
The purpose of this study was to evaluate the subchronic, reproductive, and developmental toxicity of the test material when administered daily via oral gavage.
Endpoints evaluated were survival, clinical observations, body weights, food consumption measurements, neurobehavioral assessments (spontaneous locomotor activity, functional observational battery (FOB), grip strength), parturition checks, litter evaluations, clinical pathology (hematology, coagulation, serum chemistry), and anatomic pathology, including organ weights, gross observations at necropsy, and microscopic evaluation of select tissues. Blood was collected for the analysis of thyroid hormone evaluation from all F0 animals and representative pups from each litter; analysis was conducted on the F0 males and on pups at postnatal day (PND) 13. Administration of test material at dosages of 100, 300, or 1000 mg/kg to F0 male and female rats for up to 5 weeks and 9 weeks, respectively, produced no adverse effects on body weights, food consumption, estrous cyclicity, reproductive performance, FOB, grip strength, clinical pathology, thyroid hormone, or anatomic pathology parameters.
There were no treatment-related effects on male or female F1 clinical observations, body weights, anogenital distance, and thyroid hormones, or male pup areola/nipple retention.
Therefore, the no observable adverse effect level (NOAEL) for systemic and reproductive toxicity in F0 males and females was 1000 mg/kg.
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Reproductive/Developmental Toxicity Screening Study:
A reproductive / developmental screening study according to OECD TG 422 and in compliance with GLP was performend to evaluate the subchronic, reproductive, and developmental toxicity of test material when administered daily via oral gavage.
Endpoints evaluated were survival, clinical observations, body weights, food consumption measurements, neurobehavioral assessments (spontaneous locomotor activity, functional observational battery (FOB), grip strength), parturition checks, litter evaluations, clinical pathology (hematology, coagulation, serum chemistry), and anatomic pathology, including organ weights, gross observations at necropsy, and microscopic evaluation of select tissues. Blood was collected for the analysis of thyroid hormone evaluation from all F0 animals and representative pups from each litter; analysis was conducted on the F0 males and on pups at postnatal day (PND) 13. Administration of test material at dosages of 100, 300, or 1000 mg/kg to F0 male and female rats for up to 5 weeks and 9 weeks, respectively, produced no adverse effects on body weights, food consumption, estrous cyclicity, reproductive performance, FOB, grip strength, clinical pathology, thyroid hormone, or anatomic pathology parameters.
There were no treatment-related effects on male or female F1 clinical observations, body weights, anogenital distance, and thyroid hormones, or male pup areola/nipple retention.
Therefore, the no observable adverse effect level (NOAEL) for systemic and reproductive toxicity in F0 males and females was 1000 mg/kg.
Further toxicological data of category members:
The test article belongs to the "perylene based organic pigments" category (see attached document for details on category members and for read across justification). Regarding the reproductive toxicity, additional reliable data are available for other category members. All of the studies are taken into account for the evaluation and assessment of the toxicity of the test article.
For other category members additional screening studies according to OECD TG 422 or 421 are available. In none of the studies a evidence for reproductive toxicity was found, supporting the results of this screening study.
Effects on developmental toxicity
Description of key information
Prenatal development: Read across, NOAEL (systemic toxicity/Developmental toxicity) >= 1000 mg/kg, according OECD 414, GLP compliance, 2022, K1
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Justification for type of information:
- see attached justification
- Reason / purpose for cross-reference:
- read-across source
- Dose descriptor:
- NOAEL
- Remarks:
- sytsemic toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Abnormalities:
- no effects observed
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Aug 2021 - 22 Nov 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 25 June 2018
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Wistar Hannover
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories CRL, Rhone, 327 Impasse du Domaine Les Oncines, 69210 Saint Germain Nuelles (France)
- Age at order: Males: at least 11 weeks; Females: 9 weeks
- Weight at order: Males: 325-350 g; Females: 200-225 g
- Housing: no more than 5 of one sex to a cage (before and after mating); 1 male and 1 female per cage (during mating)
- Diet: ad libitum, 4 RF 21,Mucedola S.r.l., Via G. Galilei 4, 20019 SettimoMilanese (MI), Italy
- Water: ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature: 22 °C +/- 2 °C
- Humidity: 55 % +/- 15 %
- Air changes (per hr): approximately 15-20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 19 Aug 2021 To: 22 Nov 2021 - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5 %
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Suspensions of the test item, in 0.5 % CMC, were prepared using the following procedure:
1. the required amount of test item were weighed.
2. the required amount of vehicle was added.
3. the mixture was treated with a Silverson for 3 minutes.
4. the resulting suspension was left under magnetic stirring for at least 16 hour, at room temperature, prior to dosing and during dosing
The formulation was prepared daily at concentrations of 10, 30 and 100 mg/mL. Concentrations were calculated and expressed in terms of test item as supplied.
VEHICLE
- Justification for use and choice of vehicle (if other than water): not specified
- Concentration in vehicle: not specified
- Amount of vehicle (if gavage): 10 mL/kg bw
- Concentration in vehicle: 0, 10, 40, 120 mg/ml
- Lot/batch no. (if required): not specified
- Purity: not specified - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical method was validated in ERBC Study no. A4346 in the range from 10 to 100 mg/mL. Linearity, accuracy and precision were within the limits stated in the validation protocol (r > 0.99; accuracy 85-115%; precision CV < 10%). A 28 hour stability at room temperature and a 9 day stability at 2-8°C (followed by one day at room temperature under magnetic stirring) were verified in the range from 10 to 100 mg/mL.
Samples of the preparations prepared on Week 1 and Last Week were analysed to check the homogeneity and concentration. Results of the analyses were within the acceptability limits stated in ERBC SOPs for suspensions (85-115% for concentration and CV < 10% for homogeneity).
Chemical analysis was carried out by the Analytical Chemistry Department at ERBC. - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: not specified
- Proof of pregnancy: sperm in vaginal smear or vaginal plug referred to as day 0 of pregnancy - Duration of treatment / exposure:
- from Day 6 through Day 19 post coitum (14 Days)
- Frequency of treatment:
- daily
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Control
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Mid
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High
- No. of animals per sex per dose:
- 25 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: given by Sponsor
- Fasting period before blood sampling for (rat) dam thyroid hormones: not specified
- Time of day for rat dam blood sampling: in the morning
- Other: on Day 20 post coitum - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twiche daily and once daily at weekends an public holidays
- Cage side observations: Check for mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: all animals, on day 0, 3, 6, 9, 12, 15, 18 and 20 post coitum
FOOD CONSUMPTION: Yes
- measured on day 0, 3, 6, 9, 12, 15, 18 and 20 post coitum
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: thyroid and brain
THYROID HORMONE DETERMINATION (T3, T4, TSH): Yes
- Blood sampled in the morning on day 20 post coitum (day of necropsy)
- slight isoflurane anaesthesia - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight
- Number of corpora lutea
- Number of implantations
- Number of intra-uterine deaths: Early resorptions (only placental remnants visible), Late resorptions (placental and foetal remnants visible)
- Number, sex and weight of all live foetuses
- Number and sex of dead foetuses (foetuses at termwithout spontaneous movements and breathing) and in each foetuses allocated to the skeletal examination
- Gross evaluation of placentae
- The uteri from females without visible implantations (one in group 1, 3, 4; five in group 2) were immersed in a 20% solution of ammonium sulphide to reveal evidence of embryonic death at very early stages of implantation
- The uteri from dams showing unilateral implantations on the right horn (one in group 1 and 3), were also immersed in a 20% solution of ammonium sulphide, revealing the non-pregnant left horn - Blood sampling:
- - Serum: Yes
- Volume: 1 mL
- in the morning of Day 20 post coitum - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No data
- Anogenital distance of all live rodent pups: Yes - Statistics:
- For continuous variables the significance of the differences amongst group means was assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data.
Statistical analysis of non-continuous variables was carried out by means of the Kruskal-Wallis test and intergroup differences between the control and treated groups assessed by a non-parametric version of theWilliams test. The criterion for statistical significance was p<0.05. - Indices:
- Pre-implantation loss was calculated as a percentage from the formula:
> Pre impl. Loss [%] = (no. of corpora lutea − no. of implantations) x 100/ no. of corpora lutea
Post-implantation loss was calculated as a percentage from the formula:
> Post impl. Loss [%] = (no. of implantations − no. of live foetuses) x 100/ no. of implantations
Total implantation loss was calculated as a percentage from the formula:
> Total impl. Loss [%] = (no. of corpora lutea − no. of live foetuses) x 100/ no. of corpora lutea
Sex ratios of the foetuses were calculated as the percentage of males.
All derived values (e.g., means, percentages, ratios) first were calculated within the litter and the group values derived as a mean of individual litter values. Foetal structural deviations were expressed as the percentage of affected foetuses relative to all foetuses examined per group, as well as in terms of the mean litter percentage of affected litters. - Historical control data:
- Historical control data from 2014 to 2022 was provided. Data included: foetal external abnormalities, skeletal examination, fixed visceral examination, fate of females, macroscopic observation of females at final cesarean section, litter data and sex ratio of dams with live foetuses at necropsy. Tables were extracted from reproductive toxicology historical control data.
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Hairloss was observed in one control, two mid-dose and one high dose females. Considering the low incidence of hairloss and the presence of the sign also in a control animal the observation was deemed representative of normal background variability within the Wistar Han rat.
During the treatment period a presence of couloured faeces (red) in all treated group. Considering that the test item is a red solid the colour indicated the presence of the substance in the faeces and not an abnormalities. - Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight and weight gain were unaffected in females treated up to 1000 mg/kg/day over the entire administration period.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The statistically significant increase in food consumption (29.7 g of high dose group versus 27.4 g of controls) was considered incidental and unrelated to treatment.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- no effects observed
- Description (incidence and severity):
- No changes were observed in the determination of T3, T4 and TSH.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Uterus weight, corrected maternal body weight and weight gain were not affected by treatment.
There were no treatment-related organ weight changes (brain and thyroid gland) at the end of the treatment period. Any variations were considered to be within the range of expected spontaneous changes in rats of the same age and unrelated to treatment. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment-related macroscopic observations at the end of the treatment period. Any macroscopic observations were within the range of occasionally observed and expected spontaneous changes in rats of the same age and therefore considered unrelated to treatment.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related microscopic observations in the thyroid gland at the end of the treatment period. Any microscopic observations had a comparable incidence in control and treated groups and/or are characteristically seen in untreated rats of the same age and were considered incidental and unrelated to treatment.
- Histopathological findings: neoplastic:
- no effects observed
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Dose descriptor:
- NOAEL
- Remarks:
- systemic toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Litter data of treated females were comparable to controls.
Presence of foetuses with a weight less that 2.7 g and classified as small were noted in control, mid and high dose groups. Considering that the incidence of the high dose group is lower than controls and in the absence of the dose relation trend the presence is consider incidental and unrelated to treatment. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One foetus with malformation was observed in the mid- dose group. The foetus showed unilateral fusion of thoracic arches no. 10th and 11th in combination with the fusion of the 10th and 11th ribs. Considering that no other observations were noted related to the thoracic arches or ribs and in the absence of the relationship the changes were considered spontaneous in origin.
The other changes noted were comparable between the control and the treated groups. - Visceral malformations:
- no effects observed
- Description (incidence and severity):
- The variations observed occurred with similar incidence across all groups including controls.
- Dose descriptor:
- NOAEL
- Remarks:
- developmental toxicity
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Conclusions:
- On the basis of the results, the dosage of >=1000 mg/kg/day is considered the NOAEL for maternal and embryo-foetal development.
- Executive summary:
The effects of the test material were investigated, in female Wistar Hannover rats during pregnancy and embryo-foetal development, from gestation Day 6 through Day 19 in a GLP compliant study according to OECD TG 414.
Females were mated with sexually mature males of the same strain and then assigned to 4 groups of 25 females each. The plan for this study was to investigate doses of 100, 300 and 1000 mg/kg bw/day of the test item with a dose volume of 10 mL/kg body weight, during the gestation period from Day 6 through Day 19 post coitum. Control females received the vehicle (0.5 % carboxymethyl cellulose (CMC)) at the same dose volume during the same treatment period.
Body weight, daily clinical signs and food consumption were recorded during the in vivo phase. All females were caesarean-sectioned on Day 20 post coitum and subjected to post mortem examination. Thyroid hormone determination was performed. The brain and thyroid were weighed. The number of corpora lutea, implantations, early and late intrauterine deaths, live and dead foetuses, gravid uterus weights, foetal weight and sex were recorded. All foetuses were examined for external abnormalities. The anogenital distance (AGD) in all live foetuses was recorded. Approximately one half of the foetuses in each litter was examined for fixed-visceral and skeletal abnormalities.All females survived until scheduled necropsy. No signs of discomfort or clinical symptoms from the treatment with the test item were observed. No macroscopic findings were noted during necropsy of the females. Mean food consumption, mean body weight and corrected body weight gain (corrected for the gravid uterus weight) were not affected by treatment with the test item in any dose group. Post-implantation losses and the mean number of foetuses per dam were not affected by treatment with the test item at all dose levels. No test item-related effects on foetal body weights were noted. No test item-related effects on foetal sex ratios or anogenital distance were noted in any dose group.
During the external examination of the foetuses, no test item-related abnormal findings were noted. Hormone levels of dams were comparable between groups. Females did not show any macroscopic or microscopic (thyroid) changes related to treatment. Skeletal and visceral examinations were comparable between groups.
Referenceopen allclose all
Table 1: CLINICAL SIGNS OF FEMALES – GROUP INCIDENCE
| ||||||||
Interval: 0 - 20 Days Group |
1 |
2 |
3 |
4 | ||||
Observation | (25) | (25) | (25) | (25) | ||||
APPEARANCE | a | b | a | b | a | b | a | b |
Hairloss | 1 | 4.0 | 0 | 0.0 | 2 | 8.0 | 1 | 4.0 |
| ||||||||
() = Number of animals alive at start of interval a = Number of animals affected b = Percent of animals with observation during interval |
Table 2: ABSOLUTE ORGAN WEIGHTS (g) - GROUP MEAN DATA
| ||||
Organ: Brain | Data homogeneous by Bartlett's test (Dunnett's test) | |||
Group | Control (Group 1) | 2 | 3 | 4 |
Number/group | 25 | 25 | 25 | 25 |
Mean | 1.853 | 1.848 | 1.860 | 1.851 |
Standard deviation | 0.073 | 0.066 | 0.091 | 0.070 |
Group diff. at p < 0.05 |
| 0.051 | 0.051 | 0.051 |
Group diff. at p < 0.01 |
| 0.064 | 0.064 | 0.064 |
| ||||
Analysis of variance: F ratio = 0.12; Df = 3/ 96; F probability = 0.942 Note: a * indicates group mean is significantly different from control at level of significance shown. | ||||
| ||||
Organ: Thyroid | Data homogeneous by Bartlett's test (Dunnett's test) | |||
Group | Control (Group 1) | 2 | 3 | 4 |
Number/group | 25 | 25 | 25 | 25 |
Mean | 0.0218 | 0.0236 | 0.0219 | 0.0232 |
Standard deviation | 0.0048 | 0.0037 | 0.0045 | 0.0044 |
Group diff. at p < 0.05 |
| 0.0030 | 0.0030 | 0.0030 |
Group diff. at p < 0.01 |
| 0.0037 | 0.0037 | 0.0037 |
| ||||
Analysis of variance: F ratio = 1.09; Df = 3/ 96; F probability = 0.358 Note: a * indicates group mean is significantly different from control at level of significance shown. |
Table 3: ORGAN WEIGHTS° TO BRAIN WEIGHT - GROUP MEAN DATA
| ||||
Organ: Thyroid | Data homogeneous by Bartlett's test (Dunnett's test) | |||
Group | Control (Group 1) | 2 | 3 | 4 |
Number/group | 25 | 25 | 25 | 25 |
Mean | 1.181 | 1.280 | 1.181 | 1.256 |
Standard deviation | 0.268 | 0.198 | 0.254 | 0.240 |
Group diff. at p < 0.05 |
| 0.163 | 0.163 | 0.163 |
Group diff. at p < 0.01 |
| 0.204 | 0.204 | 0.204 |
| ||||
Analysis of variance: F ratio = 1.11; Df = 3/ 96; F probability = 0.349 Note: a * indicates group mean is significantly different from control at level of significance shown. ° = expressed as % organ to brain weight ratio |
Table 4: MACROSCOPIC OBSERVATIONS OF FEMALES – FINAL SACRIFICE - GROUP INCIDENCE
| ||||
Group | 1 | 2 | 3 | 4 |
Number in group | 25 | 25 | 25 | 25 |
|
|
|
|
|
Caecum |
|
|
|
|
- Abnormal contents | 0 | 0 | 0 | 1 |
Forelimbs |
|
|
|
|
- Hairloss | 1 | 0 | 1 | 1 |
Uterus |
|
|
|
|
- Unilateral implantation | 1 | 0 | 1 | 0 |
- Not pregnant | 1 | 4 | 1 | 1 |
- Total resorption | 0 | 1 | 0 | 0 |
Whole animal |
|
|
|
|
- No abnormalities detected | 22 | 20 | 22 | 23 |
Table 5: EXTERNAL EXAMINATION OF FOETUSES - GROUP INCIDENCE
| |||||||||
Group | Organ | Cat | Observation(s) | No. Observed | Foetuses Affected | % | No. Observed | Litters Affected | %
|
|
|
|
|
|
|
|
|
|
|
1 | Whole foetus |
| No abnormalities detected | 285 | 280 | 98.25 | 24 | - | - |
| Whole foetus | AN | Small | 285 | 5 | 1.75 | 24 | 4 | 16.67 |
2 | Whole foetus |
| No abnormalities detected | 228 | 228 | 100.00 | 20 | 20 | 100.00 |
3 | Whole foetus |
| No abnormalities detected | 272 | 265 | 97.43 | 24 | - | - |
| Whole foetus | AN | Small | 272 | 7 | 2.57 | 24 | 5 | 20.83 |
4 | Whole foetus |
| No abnormalities detected | 290 | 289 | 99.66 | 24 | - | - |
| Whole foetus | AN | Small | 290 | 1 | 0.34 | 24 | 1 | 4.17 |
Table 6: SKELETAL EXAMINATION OF FOETUSES - GROUP INCIDENCE
| |||||||||
|
|
|
| No. Foetuses | No. Litters | ||||
Group | Organ | Cat | Observation(s) | Obs | Aff | % | Obs | Aff | % |
1 | Forepaw(s) | AN | Metacarpal(s) no ossification 4th | 150 | 70 | 46.67 | 24 | 23 | 95.83 |
| Lumbar vertebrae | VA | Centrum incomplete ossification | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Pelvic girdle | AN | Pubis incomplete ossification | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Ribs | AN | Wavy | 150 | 10 | 6.67 | 24 | 8 | 33.33 |
| Ribs | VA | Short 14th | 150 | 65 | 43.33 | 24 | 22 | 91.67 |
| Ribs | VA | Rudimentary 14th | 150 | 11 | 7.33 | 24 | 9 | 37.50 |
| Ribs | VA | 14 ribs | 150 | 15 | 10.00 | 24 | 9 | 37.50 |
| Sacral vertebrae | AN | Arch(es) incomplete ossification | 150 | 8 | 5.33 | 24 | 3 | 12.50 |
| Skull | AN | Hyoid no ossification | 150 | 4 | 2.67 | 24 | 3 | 12.50 |
| Skull | AN | Temporal incomplete ossification | 150 | 16 | 10.67 | 24 | 10 | 41.67 |
| Skull | AN | Frontal incomplete ossification | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Skull | AN | General incomplete ossification | 150 | 5 | 3.33 | 24 | 4 | 16.67 |
| Skull | VA | Supraoccipital incomplete ossification | 150 | 60 | 40.00 | 24 | 20 | 83.33 |
| Skull | VA | Interparietal incomplete ossification | 150 | 41 | 27.33 | 24 | 17 | 70.83 |
| Skull | VA | Parietal incomplete ossification | 150 | 28 | 18.67 | 24 | 15 | 62.50 |
| Sternebrae | AN | Fused | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Sternebrae | AN | No ossification | 150 | 2 | 1.33 | 24 | 2 | 8.33 |
| Sternebrae | VA | No ossification 5th | 150 | 7 | 4.67 | 24 | 6 | 25.00 |
| Sternebrae | VA | Incomplete ossification 5th | 150 | 22 | 14.67 | 24 | 11 | 45.83 |
| Sternebrae | VA | Incomplete ossification 6th | 150 | 43 | 28.67 | 24 | 17 | 70.83 |
| Thoracic vertebrae | AN | Centrum bipartite and asymmetical | 150 | 2 | 1.33 | 24 | 2 | 8.33 |
| Thoracic vertebrae | VA | Centrum incomplete ossification | 150 | 6 | 4.00 | 24 | 3 | 12.50 |
| Thoracic vertebrae | VA | Centrum dumb-bell shaped | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
|
|
|
|
|
|
|
|
|
|
2 | Forepaw(s) | AN | Metacarpal(s) incomplete ossification | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Forepaw(s) | AN | Metacarpal(s) no ossification 4th | 119 | 37 | 31.09 | 20 | 15 | 75.00 |
| Ribs | AN | Wavy | 119 | 9 | 7.56 | 20 | 6 | 30.00 |
| Ribs | VA | 14 ribs | 119 | 10 | 8.40 | 20 | 6 | 30.00 |
| Ribs | VA | Short 14th | 119 | 52 | 43.70 | 20 | 18 | 90.00 |
| Ribs | VA | Rudimentary 14th | 119 | 12 | 10.08 | 20 | 11 | 55.00 |
| Sacral vertebrae | AN | Arch(es) incomplete ossification | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Skull | AN | Frontal incomplete ossification | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Skull | AN | Temporal incomplete ossification | 119 | 6 | 5.04 | 20 | 4 | 20.00 |
| Skull | AN | Hyoid no ossification | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Skull | VA | Interparietal incomplete ossification | 119 | 26 | 21.85 | 20 | 11 | 55.00 |
| Skull | VA | Parietal incomplete ossification | 119 | 11 | 9.24 | 20 | 8 | 40.00 |
| Skull | VA | Supraoccipital incomplete ossification | 119 | 42 | 35.29 | 20 | 19 | 95.00 |
| Sternebrae | VA | Incomplete ossification | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Sternebrae | VA | Incomplete ossification 6th | 119 | 21 | 17.65 | 20 | 10 | 50.00 |
| Sternebrae | VA | No ossification 5th | 119 | 3 | 2.52 | 20 | 3 | 15.00 |
| Sternebrae | VA | Incomplete ossification 5th | 119 | 20 | 16.81 | 20 | 11 | 55.00 |
| Thoracic vertebrae | AN | Centrum bipartite | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Thoracic vertebrae | AN | Centrum bipartite and asymmetrical | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Thoracic vertebrae | VA | Centrum asymmetrical dumb-bell shaped | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Thoracic vertebrae | VA | Centrum dumb-bell shaped | 119 | 1 | 0.84 | 20 | 1 | 5.00 |
| Thoracic vertebrae | VA | Centrum incomplete ossification | 119 | 4 | 3.36 | 20 | 2 | 10.00 |
|
|
|
|
|
|
|
|
|
|
3 | Forepaw(s) | AN | Metacarpal(s) incomplete ossification | 144 | 4 | 2.78 | 24 | 1 | 4.17 |
| Forepaw(s) | AN | Metacarpal(s) no ossification 4th | 144 | 65 | 45.14 | 24 | 20 | 83.33 |
| Ribs | AN | Wavy | 144 | 7 | 4.86 | 24 | 5 | 20.83 |
| Ribs | MA | Fused | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Ribs | VA | 14 ribs | 144 | 16 | 11.11 | 24 | 10 | 41.67 |
| Ribs | VA | Rudimentary 14th | 144 | 11 | 7.64 | 24 | 9 | 37.50 |
| Ribs | VA | Short 14th | 144 | 78 | 54.17 | 24 | 22 | 91.67 |
| Sacral vertebrae | AN | Arch(es) incomplete ossification | 144 | 5 | 3.47 | 24 | 3 | 12.50 |
| Skull | AN | Frontal incomplete ossification | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Skull | AN | Hyoid no ossification | 144 | 4 | 2.78 | 24 | 1 | 4.17 |
| Skull | AN | General incomplete ossification | 144 | 2 | 1.39 | 24 | 2 | 8.33 |
| Skull | AN | Temporal incomplete ossification | 144 | 14 | 9.72 | 24 | 6 | 25.00 |
| Skull | VA | Parietal incomplete ossification | 144 | 28 | 19.44 | 24 | 12 | 50.00 |
| Skull | VA | Interparietal incomplete ossification | 144 | 36 | 25.00 | 24 | 14 | 58.33 |
| Skull | VA | Supraoccipital incomplete ossification | 144 | 58 | 40.28 | 24 | 21 | 87.50 |
| Sternebrae | AN | Bipartite 5th | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Sternebrae | AN | No ossification | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Sternebrae | VA | Incomplete ossification | 144 | 5 | 3.47 | 24 | 3 | 12.50 |
| Sternebrae | VA | Incomplete ossification 6th | 144 | 36 | 25.00 | 24 | 13 | 54.17 |
| Sternebrae | VA | No ossification 5th | 144 | 10 | 6.94 | 24 | 5 | 20.83 |
| Sternebrae | VA | Incomplete ossification 5th | 144 | 22 | 15.28 | 24 | 16 | 66.67 |
| Thoracic vertebrae | AN | Centrum bipartite and asymmetrical | 144 | 2 | 1.39 | 24 | 2 | 8.33 |
| Thoracic vertebrae | AN | Centrum asymmetrical ossification | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Thoracic vertebrae | AN | Centrum bipartite | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Thoracic vertebrae | MA | Arch(es) fused | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Thoracic vertebrae | VA | Centrum asymmetrical dumb-bell shaped | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
| Thoracic vertebrae | VA | Centrum incomplete ossification | 144 | 1 | 0.69 | 24 | 1 | 4.17 |
|
|
|
|
|
|
|
|
|
|
4 | Forepaw(s) | AN | Metacarpal(s) no ossification 4th | 150 | 52 | 34.67 | 24 | 19 | 79.17 |
| Ribs | AN | Wavy | 150 | 12 | 8.00 | 24 | 6 | 25.00 |
| Ribs | VA | Rudimentary 14th | 150 | 6 | 4.00 | 24 | 6 | 25.00 |
| Ribs | VA | 14 ribs | 150 | 11 | 7.33 | 24 | 8 | 33.33 |
| Ribs | VA | Short 14th | 150 | 71 | 47.33 | 24 | 21 | 87.50 |
| Sacral vertebrae | AN | Arch(es) incomplete ossification | 150 | 5 | 3.33 | 24 | 4 | 16.67 |
| Skull | AN | General incomplete ossification | 150 | 2 | 1.33 | 24 | 2 | 8.33 |
| Skull | AN | Frontal incomplete ossification | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Skull | AN | Hyoid no ossification | 150 | 4 | 2.67 | 24 | 4 | 16.67 |
| Skull | AN | Temporal incomplete ossification | 150 | 17 | 11.33 | 24 | 9 | 37.50 |
| Skull | VA | Interparietal incomplete ossification | 150 | 46 | 30.67 | 24 | 18 | 75.00 |
| Skull | VA | Supraoccipital incomplete ossification | 150 | 60 | 40.00 | 24 | 19 | 79.17 |
| Skull | VA | Parietal incomplete ossification | 150 | 30 | 20.00 | 24 | 14 | 58.33 |
| Sternebrae | AN | Asymmetrical ossification 5th | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Sternebrae | VA | Incomplete ossification 5th | 150 | 32 | 21.33 | 24 | 17 | 70.83 |
| Sternebrae | VA | No ossification 5th | 150 | 4 | 2.67 | 24 | 3 | 12.50 |
| Sternebrae | VA | Incomplete ossification | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Sternebrae | VA | Incomplete ossification 6th | 150 | 33 | 22.00 | 24 | 13 | 54.17 |
| Thoracic vertebrae | AN | Centrum bipartite | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Thoracic vertebrae | VA | Centrum asymmetrical dumb-bell shaped | 150 | 1 | 0.67 | 24 | 1 | 4.17 |
| Thoracic vertebrae | VA | Centrum incomplete ossification | 150 | 4 | 2.67 | 24 | 4 | 16.67 |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Prenatal Developmental Toxicity:
As no data for the test substance is available regarding prenatal developmental toxicity a read-across to the category member CAS 5521-31-3 was performed.
Females were mated with sexually mature males of the same strain and then assigned to 4 groups of 25 females each. The plan for this study was to investigate doses of 100, 300 and 1000 mg/kg bw/day of the test item with a dose volume of 10 mL/kg body weight, during the gestation period from Day 6 through Day 19 post coitum. Control females received the vehicle (0.5 % carboxymethyl cellulose (CMC)) at the same dose volume during the same treatment period.
Body weight, daily clinical signs and food consumption were recorded during the in vivo phase. All females were caesarean-sectioned on Day 20 post coitum and subjected to post mortem examination. Thyroid hormone determination was performed. The brain and thyroid were weighed. The number of corpora lutea, implantations, early and late intrauterine deaths, live and dead foetuses, gravid uterus weights, foetal weight and sex were recorded. All foetuses were examined for external abnormalities. The anogenital distance (AGD) in all live foetuses was recorded. Approximately one half of the foetuses in each litter was examined for fixed-visceral and skeletal abnormalities.
All females survived until scheduled necropsy. No signs of discomfort or clinical symptoms from the treatment with the test item were observed. No macroscopic findings were noted during necropsy of the females. Mean food consumption, mean body weight and corrected body weight gain (corrected for the gravid uterus weight) were not affected by treatment with the test item in any dose group. Post-implantation losses and the mean number of foetuses per dam were not affected by treatment with the test item at all dose levels. No test item-related effects on foetal body weights were noted. No test item-related effects on foetal sex ratios or anogenital distance were noted in any dose group.
During the external examination of the foetuses, no test item-related abnormal findings were noted. Hormone levels of dams were comparable between groups. Females did not show any macroscopic or microscopic (thyroid) changes related to treatment. Skeletal and visceral examinations were comparable between groups.
Further toxicological data of category members:
The test article belongs to the "perylene based organic pigments" category (see attached document for details on category members and for read across justification). Regarding the developmental toxicity, additional reliable data are available for other category members. All of the studies are taken into account for the evaluation and assessment of the toxicity of the test article.
For other category members and the test material itself, additional screening studies according to OECD TG 422 or 421 are available. In none of the studies a evidence for reproductive or developmental toxicity was found, supporting the results of this read-across study.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available screening study is reliable and suitable for classification purposes under Regulation 1272/2008. No adverse effects on fertility or development were observed in a screening study in rats (OECD 422) and no adverse effects were observed in a teratogenicity/developmental toxicity study in rats (OECD 414). As a result, the substance is not considered to be classified for fertility or developmental toxicity under Regulation (EC) No. 1272/2008, as amended for the fourteenth time in Regulation (EC) No. 2020/217.
During the thirteen days covered in the screening study, no effects via lactation were observed.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)